Publication
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Authors not recorded
Clin Cancer Res2023PMID 36806911PMC10233352stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugDurvalumabcivic_curation1.00
- variantHighcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36806911
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| Durvalumab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12850This retrospective analysis of the Phase 3 EAGLE trial (NCT02369874) evaluated tissue tumor mutational burden (tTMB) and blood TMB (bTMB) as predictive biomarkers in platinum-refractory recurrent or m… (full text at CIViC) PMID 36806911 · Wildsmith et al., 2023 · Open in CIViC | civic |